Revenue in the third quarter amounted to 158.5 MSEK, representing growth of 15.3%
Revenue amounted to 158.5 (137.5) MSEK in the third quarter, representing growth of 15,3%. Adjusted EBITDA amounted to 43.7 (32.6) MSEK, representing growth of 34.0%. Cambio acquired 100% of the shares in MittVaccin, a Swedish company within the vaccination record business. Revenue during January - September amounted to 518.8 (20 Feb - 30 Sep, 2019; 334.7) MSEK. Adjusted EBITDA amounted to 143.9 (20 Feb -30 Sep 2019; 67.1) MSEKComments from Peter Gille, CEO As a result of the spread of the Corona virus many people are living with challenging conditions and many have lost their lives.